|
新闻
Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
Palo Alto, CA - October 24, 2007 Vivo Ventures, a venture capital firm
specializing in life science investments, today announced that James
Huang will join the firm as an Executive in Residence. With his
extensive business development and operating experience, James will work
with Vivo's portfolio companies while enhancing the firm's presence in
Asia. "We are excited about James coming on board and what he will be
able to bring to Vivo," said Frank Kung, Managing Partner of Vivo
Ventures. "His extensive relationships throughout the pharmaceutical
industry, his impressive track record in closing multiple business
development partnerships, and his experience in building companies makes
him a valuable asset to our team and our portfolio companies." "Vivo
Ventures is one of the best recognized life sciences venture firms in
the U.S. and in Asia. I am very enthused about the opportunity to
contribute the success of Vivo's existing and future portfolio
companies," commented James Huang.
About James Huang
With 20 years of experience in the pharmaceutical industry, James joins
Vivo from Anesiva, where he has served as president since September
2005. Previously, he had served as Anesiva's senior vice president of
business development and commercial operations. He joined Anesiva from
Tularik Inc., where he held the position of vice president of business
development and commercial operations and led the development and
negotiation of commercial and scientific collaborations, alliances, and
licensing agreements. Among the most notable include: a collaboration
with Medarex to develop and commercialize human therapeutic antibodies;
a collaboration with Sankyo to jointly discover and develop human
therapeutics related to orphan G-protein coupled receptors (GPCRs); as
well as other technology collaborations and corporate development
acquisitions. Mr. Huang also guided strategic planning and execution for
Tularik's marketing programs. Prior to Tularik, Mr. Huang was product
director of Avandia and diabetes at SmithKline Beecham PLC (now
GlaxoSmithKline) where he launched Avandia (rosiglitazone maleate),
which achieved over $2 billion in U.S. sales last year. In addition, he
held positions in New Product Development and Worldwide Business
Development, negotiating and closing in-licensing agreements for
compounds, and managing technology collaborations and corporate
development acquisitions. Mr. Huang also held various positions in
Bristol-Myers Squibb's Worldwide Strategic Product Planning, Managed
Care and Sales and Marketing organizations, and research and development
positions at Alza Corporation (now a Johnson & Johnson company). He
received an M.B.A. from Stanford Graduate School of Business and earned
a B.S. degree in Chemical Engineering at the University of California,
Berkeley.
« 回 新闻
|
